Literature DB >> 11328288

Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.

S Fontana1, H E Gerritsen, J Kremer Hovinga, M Furlan, B Lämmle.   

Abstract

Complete deficiency of von Willebrand factor-cleaving protease (VWF-cp) has recently been identified as a pathogenetically important factor for thrombotic thrombocytopenic purpura (TTP). Microangiopathic haemolytic anaemia (MAHA) with thrombocytopenia in patients with metastasizing neoplasms is clinically similar to TTP, however, the pathogenesis of the condition is unclear. Partial deficiency of VWF-cp in metastasizing malignancy has recently been reported in patients without MAHA. Our study shows normal or subnormal VWF-cp activity in four patients with metastasizing neoplasia-associated MAHA but, in contrast to classical TTP, no complete deficiency of VWF-cp despite the full clinical picture of MAHA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328288     DOI: 10.1046/j.1365-2141.2001.02704.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Microangiopathic hemolysis refractory to plasmapheresis responding to docetaxel and cisplatin: a case report.

Authors:  George Marcoullis; Lool Abebe; Dharamvir Jain; Richard Talusan; Niyati Bhagwati; Peter H Wiernik
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

Review 3.  Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.

Authors:  Rebecca L Ruebner; Lawrence Copelovitch; Nicholas F Evageliou; Michelle R Denburg; Jean B Belasco; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-12-07       Impact factor: 3.714

5.  Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and Cyclophosphamide.

Authors:  Samuel Jalali; Dakota Jenneman; Ankita Tandon; Hung Khong
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

6.  Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.

Authors:  D Li; J Xiao; M Paessler; X L Zheng
Journal:  Thromb Haemost       Date:  2011-09-08       Impact factor: 5.249

7.  Breast Cancer-Associated Thrombotic Microangiopathy.

Authors:  Anne C Regierer; Dagmar Kuehnhardt; Carsten-Oliver Schulz; Bernd Flath; Christian F Jehn; Christian W Scholz; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2011-12-15       Impact factor: 2.860

Review 8.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 9.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.